Skip to main content

Table 2 Baseline characteristics of the study population

From: Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 – a nationwide study

 

Non-diabetes

Diabetes

No CAD

Single vessel disease

Double vessel disease

Triple vessel disease

Diffuse disease

No CAD

Single vessel disease

Double vessel disease

Triple vessel disease

Diffuse disease

N (%)

56.922 (61.52)

13.627 (14.73)

6.409 (6.93)

7.022 (7.59)

8.542 (9.23)

13.134 (54.80)

3.320 (13.85)

2.111 (8.81)

2.997 (12.50)

2.407 (10.04)

Sex, male (%)

33.361 (58.61)

9.499 (69.71)

4.777 (74.54)

5.594 (79.66)

4.860 (56.90)

8.376 (63.77)

2.298 (69.22)

1.574 (74.56)

2.299 (76.71)

1.528 (63.48)

Age, mean (IQR*)

63.17 (55–72)

63.51 (55–72)

66.95 (59–75)

69.57 (63–77)

66.13 (59–74)

63.84 (57–72)

63.93 (57–72)

65.91 (59–73)

67.29 (61–74)

64.96 (58–72)

Smoking (%)

14.042 (24.67)

4.983 (36.57)

2.064 (32.20)

1.923 (27.39)

2.100 (24.58)

3.089 (23.52)

1.030 (31.02)

624 (29.56)

787 (26.26)

559 (23.22)

B-blockers* (%)

22.256 (39.10)

3.112 (22.84)

1.931 (30.13)

2.516 (35.83)

2.723 (31.88)

6.609 (50.32)

1.040 (31.33)

795 (37.66)

1.244 (41.51)

916 (38.06)

Statins (%)

22.529 (39.58)

3.360 (24.66)

2.078 (32.42)

2.771 (39.46)

2.981 (34.90)

8.515 (64.83)

1.462 (44.04)

1.011 (47.89)

1.611 (53.75)

1.332 (55.34)

ACE-I* (%)

18.914 (33.23)

3.076 (22.57)

1.817 (28.35)

2.277 (32.43)

2.632 (30.81)

8.008 (60.97)

1.470 (44.28)

985 (46.66)

1.600 (53.39)

1.307 (54.30)

Spironolacton (%)

2.314 (4.07)

250 (1.83)

179 (2.79)

225 (3.20)

296 (3.47)

1.048 (7.98)

125 (3.77)

103 (4.88)

188 (6.27)

158 (6.56)

Loop diuretics (%)

7.595 (13.34)

885 (6.49)

605 (9.44)

903 (12.86)

1.055 (12.35)

3.430 (26.12)

508 (15.30)

385 (18.24)

693 (23.12)

554 (23.02)

ASA* (%)

25.578 (44.94)

3.630 (26.64)

2.234 (34.86)

3.026 (43.09)

3.132 (36.67)

7.880 (60.00)

1.283 (38.64)

991 (46.94)

1.589 (53.02)

1.124 (46.70)

VKA* (%)

4.711 (8.28)

563 (4.13)

332 (5.18)

360 (5.13)

717 (8.39)

1.393 (10.61)

187 (5.63)

131 (6.21)

179 (5.97)

252 (10.47)

Platlet inhibitors (%)

26.598 (46.73)

3.849 (28.25)

2.371 (36.99)

3.208 (45.68)

3.346 (39.17)

8.187 (62.33)

1.374 (41.39)

1.042 (49.36)

1.690 (56.39)

1.207 (50.15)

Digoxin (%)

2.248 (3.95)

311 (2.28)

199 (3.11)

266 (3.79)

468 (5.48)

924 (7.04)

137 (4.13)

114 (5.40)

181 (6.04)

199 (8.27)

Atrial Fibrillation (%)

5.007 (8.80)

791 (5.80)

425 (6.63)

518 (7.38)

1.041 (12.19)

1.543 (11.75)

258 (7.77)

189 (8.95)

244 (8.14)

3.621 (15.04)

IHD* (%)

4.812 (8.45)

1.134 (8.32)

859 (13.40)

1.234 (17.57)

780 (9.13)

1.789 (13.62)

401 (12.08)

398 (18.85)

702 (23.42)

281 (11.67)

Renal Disease (%)

897 (1.58)

132 (0.97)

91 (1.42)

123 (1.75)

144 (1.69)

383 (2.92)

74 (2.23)

60 (2.84)

82 (2.74)

81 (3.37)

Hypertension (%)

9.099 (15.99)

1.772 (13.00)

1.029 (16.06)

1.290 (18.37)

1.877 (21.97)

4.115 (31.33)

871 (26.23)

599 (28.38)

932 (31.10)

916 (38.06)

Thromboembolus(%)

4.128 (7.25)

893 (6.55)

511 (7.97)

763 (10.87)

829 (9.70)

1.308 (9.96)

326 (9.82)

228 (10.80)

409 (13.65)

273 (11.34)

  1. Continuous variables are presented as means (with standard deviation values) and discrete variables as percentages (%). B-blocker Beta-blocker, ACEI Angiotensin converting enzyme inhibitors, ASA Acetylsalicylic acid, VKA Vitamin K antagonist
  2. *Beta-Blockers *Angiotensin Converting Enzyme Inhibitors *Acetylsalicylic Acid *Vitamin K Antagonists *Ischemic Heart Disease *Interquartile range
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us